NCT00909441已完成不适用
Sentinel Node Biopsy Following NeoAdjuvant Chemotherapy in Biopsy Proven Node Positive Breast Cancer: A Multi-institutional Prospective Study Furthering the Treatment of Breast Cancer
Centre hospitalier de l'Université de Montréal (CHUM)2 个研究点 分布在 1 个国家目标入组 153 人开始时间: 2009年2月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 153
- 试验地点
- 2
- 主要终点
- The false negative rate of sentinel node biopsy following neoadjuvant chemotherapy in biopsy proven node positive breast cancer.
研究概览
简要总结
Title of Study: Sentinel node biopsy following neoadjuvant chemotherapy in biopsy proven node positive breast cancer.
Objectives of the study:
Primary objective
- Evaluate the accuracy of sentinel node biopsy in breast cancer patients presenting with positive nodal disease, proven by ultrasound guided fine needle aspiration, following neoadjuvant chemotherapy.
Secondary objectives
- Evaluate the technical success of sentinel node biopsy following neoadjuvant chemotherapy.
- Evaluate the accuracy of clinical examination and ultrasound examination of the axilla in identifying the presence of residual disease in the axilla following neoadjuvant chemotherapy in biopsy proven node positive breast cancer patients.
Number of patients:
N = 300
Population:
Patients with unresected breast cancer that are eligible for neoadjuvant chemotherapy that present with biopsy proven positive axillary nodes.
Study duration:
From February 2009 to February 2012 - 3 years
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Conditions for patient eligibility
- •Inclusion criteria:
- •Patients must be female.
- •Patients must be 18 years of age or older.
- •Patients with stage IIA, IIB, IIIA (T1-3 and N1-2) breast cancer. Clinical N0 accepted if biopsy proven node disease.
- •Patients that have biopsy proven positive axillary disease made by core needle biopsy or fine needle aspiration .
- •Patients that accept to undergo neoadjuvant chemotherapy; patients are eligible until the day of surgery.
- •Patients with bilateral breast cancer are eligible. Sentinel node biopsy is allowed on the contralateral breast if there is no disease in the axilla prior to chemotherapy.
- •Patients that understand, accept and have signed the approved consent form.
排除标准
- •Patients with inflammatory breast cancer.
- •Patient with stage IIIB, IIIC or IV breast cancer (T4 and N3) Patients with clinical N3 disease are excluded.
- •Patients that have had previous axillary dissection or an axillary sentinel node biopsy; (patients that have had excisional biopsy or ipsilateral tumorectomy are eligible).
- •Patients that have had previous radiotherapy to the axillary nodes
- •Patients that have had mammary reduction
- •Patients that are medically unfit to receive chemotherapy, as evaluated by the treating physician.
- •If the injection of blue dye is planned, patients with hypersensitivity or allergy to isosulfan blue, Patent blue or methylene blue or radiocolloid dye are ineligible.
- •Patients who are pregnant or breast feeding .
- •Psychiatric or addictive disorders or other conditions that preclude the patient from meeting the study requirements.
结局指标
主要结局
The false negative rate of sentinel node biopsy following neoadjuvant chemotherapy in biopsy proven node positive breast cancer.
时间窗: 4-7 months
次要结局
- Evaluate the accuracy of clinical evaluation and ultrasound examination in determining the presence of residual disease following neoadjuvant chemotherapy in biopsy proven node positive breast cancer.(3-6 months)
- Evaluate the technical success rate of sentinel node biopsy following neoadjuvant chemotherapy(4-7 months)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
不适用
ICG and Blue Dye Guided Sentinel Lymph Node Biopsy in Patients Underwent Neoadjuvant TherapyBreast NeoplasmsNCT02869815Peking University People's Hospital150
尚未招募
不适用
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Initially Node Positive Breast Cancer Patients, Could it Omit Axillary Dissection ?Sentinel Lymph NodeNCT06130241Assiut University30
进行中（未招募）
不适用
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast CancerLocally Advanced Breast CancerBreast CancerNCT03255577Memorial Sloan Kettering Cancer Center162
尚未招募
3 期
Comparison of Fluorescein plus blue dye and blue dye alone in sentinel lymph node biopsy of breast cancer patients after neoadjuvant chemotherapyCTRI/2020/10/028337AIIMS Jodhpur
已完成
3 期
Sentinel lymph node biopsy after neoadjuvant treatment of breast cancer using blue dye, radioisotope, and indocyanine greeocally advanced breast cancer patientsLocally advanced breast cancer patientssentinel lymphnodesSentinel lymph node biopsyindocyanine greenneoadjuvant chemotherapyTCTR20200730003Department of surgery Faculty of medicine Ramathibodi Hospital , Mahidol university , Bangkok , Thai21